Literature DB >> 425967

The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure.

C V Leier, D V Unverferth, R E Kates.   

Abstract

Plasma dobutamine concentrations and hemodynamic and noninvasive cardiac measurements were made during dobutamine infusions in eight patients with congestive cardiomyopathy and low output heart failure. Plasma concentrations correlated well with infusion rates (2.5, 5.0, 7.5 and 10 microgram/kg/min). Cardiac output and stroke volume increased linearly, whereas pulmonary capillary wedge pressure, and total pulmonary and systemic resistances decreased linearly with increasing dobutamine concentrations. No constant relationship existed between plasma dobutamine levels and changes in heart rate or mean arterial pressure. The noninvasive left ventricular function data (echocardiographic and systolic time intervals) correlated linearly with plasma concentrations and suggest that these noninvasive technics be employed in guiding the administration of this new inotropic agent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 425967     DOI: 10.1016/0002-9343(79)90537-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 2.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Dobutamine in elderly septic shock patients refractory to dopamine.

Authors:  B Tell; T C Majerus; L Flancbaum
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 4.  The pharmacokinetics and pharmacodynamics of newer inotropic agents.

Authors:  M L Rocci; H Wilson
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 5.  Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.

Authors:  C Steinberg; D A Notterman
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 6.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 7.  Catecholamines in critical care. The commonly used catecholamines: receptor and clinical profile, indications and dosages.

Authors:  F W Santman
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

8.  Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.

Authors:  W S Colucci; A R Denniss; G F Leatherman; R J Quigg; P L Ludmer; J D Marsh; D F Gauthier
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Ranolazine may exert its beneficial effects by increasing myocardial adenosine levels.

Authors:  D Elizabeth Le; Catherine M Davis; Kevin Wei; Yan Zhao; Zhiping Cao; Matthew Nugent; Kristin L Lyon Scott; Lijuan Liu; Shanthi Nagarajan; Nabil J Alkayed; Sanjiv Kaul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-13       Impact factor: 4.733

10.  Engineered Cardiac Tissues Generated in the Biowire™ II: A Platform for Human-Based Drug Discovery.

Authors:  Nicole T Feric; Isabella Pallotta; Rishabh Singh; Danielle R Bogdanowicz; Marietta Gustilo; Khuram Chaudhary; Robert N Willette; Tim Chendrimada; Xiaoping Xu; Michael P Graziano; Roozbeh Aschar-Sobbi
Journal:  Toxicol Sci       Date:  2019-08-06       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.